AI Article Synopsis
- Bullous pemphigoid is a common autoimmune blistering disease primarily affecting older adults, often linked to serious health conditions like diabetes and heart disease.
- It involves the body producing autoantibodies that attack proteins in the skin, leading to painful blisters and a high mortality rate within the first year.
- A case study is presented of a diabetic patient on hemodialysis with severe bullous pemphigoid who was successfully treated with double filtration plasmapheresis, which helped eliminate the need for systemic steroids.
Article Abstract
Bullous pemphigoid is the most common autoimmune blistering disease induced by autoantibodies against basement membrane anchoring proteins (anti-BP-180 and anti-BP-230). The disease generally appears after the age of 70 and is associated with a 23.5% 1-year mortality, especially in diabetics, or in the presence of ischemic heart disease and high anti-BP-180. Treatment starts with topical steroids but some patients may require oral steroids and systemic immunosuppression. We, hereby, discuss a diabetic patient on chronic hemodialysis, with severely relapsed bullous pemphigoid under biotherapy with omalizumab, who was successfully treated with five sessions of double filtration plasmapheresis, thus avoiding the need for systemic steroids.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jca.22133 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Macrophages in inflammatory skin diseases and skin tumors.
Front Immunol
December 2024
Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Article Synopsis
- - Macrophages are key immune cells that play diverse roles in the body, especially in the skin, which is the largest immune organ and is crucial for studying various skin-related conditions.
- - This review focuses on recent findings about macrophages in inflammatory skin diseases like atopic dermatitis and psoriasis, as well as skin tumors such as melanoma and cutaneous T-cell lymphoma.
- - The goal is to enhance understanding of how macrophages contribute to these diseases and explore potential new treatments targeting them.
Milia En Plaque After Bullous Pemphigoid: An Unusual Sequela.
Cureus
November 2024
Dermatology, Texas Tech University Health Sciences Center, Lubbock, USA.
We present the case of a 36-year-old paraplegic woman with a history of spinal cord injury who developed a generalized blistering rash, later diagnosed as bullous pemphigoid (BP). During her hospitalization, she was treated with prednisone and rituximab infusions, transitioning to maintenance therapy with topical steroids, doxycycline, and nicotinamide. A year later, she presented with concerns about a BP flare on her feet.
View Article and Find Full Text PDFSuccessful Treatment of Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid with Omalizumab: A Case Report and Review of the Literature.
Clin Cosmet Investig Dermatol
December 2024
Department of Dermatology, Guangzhou Dermatology Hospital, Guangzhou, 510095 People's Republic of China.
Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by enhancing the immune system's ability to target cancer cells. However, ICIs can lead to immune-related adverse events (irAEs), including dermatologic manifestations such as bullous pemphigoid (BP).
Objective: To evaluate the efficacy and safety of omalizumab and other biologics in the treatment of ICI-induced refractory bullous pemphigoid and to derive a strategy for selecting biologic treatments for this condition.
Dupilumab, corticosteroids and their combination for the treatment of bullous pemphigoid.
An Bras Dermatol
December 2024
Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, China. Electronic address:
Background: Conventional systemic corticosteroid therapy for bullous pemphigoid (BP) has been challenged due to severe adverse events. Dupilumab has emerged as an alternative therapeutical option of BP patients.
Objectives: To evaluate the efficacy of dupilumab monotherapy and the combination with medium/low-dose corticosteroids for BP treatment.
Assessing usability of electronic patient-reported outcome measures in older people with and without a rare dermatologic disorder.
J Patient Rep Outcomes
December 2024
eCOA Science, Clario, Geneva, Switzerland.
Background: Robust and well-defined data collection is important when using electronic patient-reported outcome measures (ePROMs) in clinical studies. Questions have been raised as to whether older age may be a barrier to data collection due to patients' unfamiliarity with electronic devices. Older adults may also have underlying health conditions that affect their ability to fill out patient-reported outcome measures (PROMs) on electronic devices.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!